{
  "claim_id": "claim_005",
  "claim": "Flublok (quadrivalent) was evaluated in the pivotal trial against Fluarix (quadrivalent standard-dose vaccine).",
  "document": "FlublokPI",
  "additional_evidence_check": {
    "checked_for_more": true,
    "found_additional": true,
    "additional_count": 1
  },
  "completeness_stats": {
    "existing_evidence": 2,
    "new_evidence_found": 1,
    "total_evidence": 3
  },
  "combined_evidence": [
    {
      "id": 1,
      "quote": "Study 6 (NCT02285998) enrolled subjects 50 years of age and older, randomized to receive Flublok Quadrivalent or Comparator (Fluarix Quadrivalent, manufactured by GlaxoSmithKline) as an active control [see Clinical Studies (14)]. The safety analysis population included 4328 Flublok Quadrivalent recipients and 4344 Comparator vaccine recipients.",
      "relevance_explanation": "This quote explicitly states that Flublok Quadrivalent was evaluated in a trial (Study 6) where it was directly compared against Fluarix Quadrivalent, confirming that the pivotal trial used Fluarix Quadrivalent as the comparator."
    },
    {
      "id": 2,
      "quote": "The primary efficacy endpoint of Study 6 was rtPCR-positive, protocol defined ILI due to any strain of influenza. Attack rates and relative vaccine efficacy (rVE), defined as 1 - [Attack rate Flublok Quadrivalent / Attack Rate Comparator], were calculated for the total efficacy population (n=8604) for the primary efficacy endpoint and for several alternative efficacy endpoints (Table 5). ... Comparator=U.S.-licensed quadrivalent inactivated influenza vaccine, Fluarix Quadrivalent, manufactured by GlaxoSmithKline;",
      "relevance_explanation": "This quote details the design of Study 6, specifying that the comparator was Fluarix Quadrivalent, and that efficacy was measured directly between Flublok Quadrivalent and Fluarix Quadrivalent, supporting the claim."
    },
    {
      "id": "comp_1",
      "quote": "Comparator, Fluarix Quadrivalent, manufactured by GlaxoSmithKline) (n=4489). Among randomized subjects, 58% were female, 80% white, 18% black/African-American, other races, and 5% of Hispanic/Latino ethnicity. A total of 5186 (60%) subjects were...",
      "relevance_explanation": "This quote explicitly identifies Fluarix Quadrivalent, manufactured by GlaxoSmithKline, as the comparator in a randomized study population, directly supporting the claim that Flublok Quadrivalent was evaluated against Fluarix Quadrivalent in a pivotal trial.",
      "source": "completeness_check",
      "metadata": {
        "extraction_round": 2,
        "targeted_aspect": "general"
      }
    }
  ],
  "completeness_assessment": {
    "missing_aspects": []
  },
  "model_used": "gpt-4.1"
}